NanoAntibiotics, Inc. — Form 10-Q Summary
Filing identity: The supplied filing is for NanoAntibiotics, Inc., not BIOVIE INC. It covers the quarter and six months ended December 31, 2015, the company’s fiscal second quarter. Financial statements are unaudited except the June 30, 2015 balance-sheet comparison.
Business context and reporting period
NanoAntibiotics describes itself as an early-stage biotechnology company developing broad-spectrum antibiotics. Its candidates had been tested only in cell-based assays; animal efficacy and toxicity studies had not been conducted. The company reported that research and development was on hold while it pursued licensing rights and evaluated other opportunities.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2015 | Six months ended Dec. 31, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $49,928 | $104,555 | $70,591 quarterly; $129,481 six-month |
| Net loss | $49,878 | $104,444 | $70,485 quarterly; $129,261 six-month |
| Net loss per share | $0.00 | $0.00 | $0.00 in both comparable periods |
- Gross margin was zero because there were no sales or cost of goods sold. No meaningful operating margin was reported.
- Six-month R&D expense was $0, compared with $3,400 in the prior-year period. Six-month payroll expense was $80,738 and professional fees were $18,017.
- Cash was $249,556 at December 31, 2015, versus $267,481 at June 30, 2015. Six-month operating cash use was $17,925; there were no investing or financing cash flows.
- Current liabilities were $404,338, including $403,688 of accrued payroll; accounts payable was $650. Current assets were $249,556, resulting in a $154,782 working-capital deficit. The balance sheet reports no debt.
- Stockholders’ deficit was $154,782. Shares outstanding were 87,210,000 at December 31, 2015.
Material changes versus comparable periods
- Quarterly net loss improved to $49,878 from $70,485; six-month net loss improved to $104,444 from $129,261. Operating expenses also declined in both comparisons.
- Cash use from operations fell to $17,925 for the six months, from $44,798 in the prior-year period. Cash nevertheless declined by $17,925 from the start of the current six-month period.
- Accrued payroll increased by $80,738 from June 30 to December 31, 2015, while total liabilities exceeded total assets at period-end.
Outlook, risks, and unusual items
- Management said the company lacked sufficient funds for the next 12 months and estimated it needed approximately $1 million in additional financing. It believed existing cash would last only until June 30, 2016.
- Subject to obtaining financing, management estimated next-12-month spending of $750,000 for R&D and licensing/development, $50,000 for corporate overhead, $50,000 for equipment, and $150,000 for staffing. The filing cautions that estimates may be inaccurate.
- The company explicitly disclosed substantial doubt about its ability to continue as a going concern. It had no committed financing source and warned it might scale back or halt development, seek licensing or strategic transactions, sell the company, or cease operations if funding could not be secured.
- Other stated risks include obtaining licensing rights, developing and validating compounds, regulatory approval, and securing funding. The company cautioned that its compounds might never work, be approved, or generate revenue.
- The company had a five-year office lease through December 2018, requiring $357 monthly. The CEO/CFO employment agreement stated a $150,000 annual salary and expired June 30, 2015; the filing says salary would continue at that rate until a new agreement is reached.
- Management concluded disclosure controls and procedures were not effective as of December 31, 2015. No material change in internal control over financial reporting was reported during the quarter.
- No material legal proceedings, unregistered equity sales, or off-balance-sheet arrangements were reported. A full valuation allowance was maintained against deferred tax assets.
Important facts for investors to verify
- Confirm the intended issuer: the request identifies BIOVIE INC., but the filing names NanoAntibiotics, Inc.
- Confirm the intended reporting period: the filing is for the quarter ended December 31, 2015, not a calendar second quarter.
- Assess the going-concern warning, financing requirement, cash runway, and feasibility of the stated $1 million funding plan.
- Review accrued payroll of $403,688, the working-capital deficit, and the employment terms that continued after the stated agreement expiration.
- Verify licensing progress and the status of research, animal studies, and development plans, which the filing says were on hold or not yet undertaken.
- Consider the disclosed ineffective disclosure controls and the associated reporting risk.